Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Alzheimer's Disease
- Healthy Volunteers
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Other
Participation Requirements
- Age
- Between 50 years and 85 years
- Gender
- Both males and females
Description
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects. The specific objectives are: To expand the safety and tolerability profile for the administration of [18F]APN-1607 and PET scanning. T...
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects. The specific objectives are: To expand the safety and tolerability profile for the administration of [18F]APN-1607 and PET scanning. To assess regional patterns of [18F]APN-1607 uptake. To determine the Braak stage equivalent reflected by [18F]APN-1607 uptake patterns. To evaluate the relationship between regional measures of [18F]APN-1607 uptake and demographic characteristics, eg, age and gender; biological characteristics, eg, apolipoprotein E epsilon 4 (APOE4) carrier status and measures of A? burden; and clinical characteristics, eg, measurements of AD disease severity, such as National Institute on Aging and Alzheimer's Association (NIA-AA) diagnosis, Mini-mental Status Exam (MMSE) score, and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAScog).
Tracking Information
- NCT #
- NCT04141150
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: David Russell, M.D., Ph.D Invicro
Get Well Soon